Empresa Alnylam Pharmaceuticals, Inc.
Acciones
ALNY
US02043Q1076
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
149,4 USD | -1,20 % | -0,71 % | -21,95 % |
Resumen de negocios
Número de empleados: 2 100
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100,0
%
| 1 037 | 100,0 % | 1 828 | 100,0 % | +76,23 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
69,8
%
| 616 | 59,4 % | 1 276 | 69,8 % | +107,21 % |
Europe
21,8
%
| 315 | 30,4 % | 399 | 21,8 % | +26,83 % |
Rest of the World
8,4
%
| 107 | 10,3 % | 153 | 8,4 % | +43,31 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 61 | 19/09/16 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13/08/19 |
Piyush Sharma
CMP | Compliance Officer | - | 21/09/22 |
Chief Tech/Sci/R&D Officer | - | 01/08/17 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/01/05 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/15 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 29/10/14 |
Joshua Brodsky
IRO | Public Communications Contact | - | 01/02/21 |
Investor Relations Contact | 43 | 01/09/15 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18/12/15 |
Charles Sigal
BRD | Director/Board Member | 72 | 22/08/22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10/01/19 |
Amy Schulman
CHM | Chairman | 63 | 01/07/14 |
Phillip Sharp
FOU | Founder | 79 | 14/06/02 |
Peter Kellogg
BRD | Director/Board Member | 67 | 07/03/23 |
Michael Bonney
BRD | Director/Board Member | 65 | 17/12/14 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 23/04/12 |
Colleen Reitan
BRD | Director/Board Member | 64 | 01/06/18 |
Chief Executive Officer | 61 | 19/09/16 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 126 491 778 | 125 969 953 ( 99,59 %) | 0 | 99,59 % |
Información de la empresa
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.comSector
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-21,95 % | 18,9 mil M | |
+33,63 % | 50,93 mil M | |
-0,09 % | 42,12 mil M | |
+49,62 % | 42,05 mil M | |
-4,96 % | 29,18 mil M | |
+11,18 % | 26,02 mil M | |
+8,61 % | 13,21 mil M | |
+24,73 % | 12,17 mil M | |
+28,31 % | 12,16 mil M | |
-6,26 % | 11,42 mil M |
- Bolsa de valores
- Acciones
- Acción ALNY
- Empresa Alnylam Pharmaceuticals, Inc.